NASM's Understanding Weight Loss Medications offers fitness and wellness professionals comprehensive, evidence-based research, along with exercise, nutrition, and behavioral strategies to support ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...

Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could outperform tirzepatide. The injectable version of the candidate, tentatively ...

GLP-1 agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists currently prescribed for weight-related conditions include Semaglutide (brand names Ozempic, Wegovy) and Tirzepatide ...